Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.
暂无分享,去创建一个
G. Mufti | R. Marcus | R. Ireland | H. de Lavallade | Z. Lim | A. Ho | L. Barber | S. Devereux | A. Pagliuca | M. Kenyon | V. Potter | J. Marsh | P. Krishnamurthy | Abdel Dhouri